Milanova Tsveta 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
Milanova Tsveta
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common stock
2026-01-05+8,475→ 37,665 total - Sale
Common stock
2026-01-05$27.02/sh−2,872$77,601→ 34,793 total - Exercise/Conversion
Restricted stock units
2026-01-05−8,475→ 0 total→ Common stock (8,475 underlying)
Footnotes (3)
- [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F3]The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.